Compare Estee Lauder Companies Inc (EL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs GSK plc — how do they compare? Estee Lauder Companies Inc trades at $88.31 (market cap $31.76B), while GSK plc trades at $50.41 (market cap $102.60B). The key difference: GSK plc is far larger — about 3.2× Estee Lauder Companies Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| EL | GSK | |
|---|---|---|
Market Cap | $31.76B | $102.60B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $61.18 |
52-Week Low | $67.23 | $38.22 |
Enterprise Value | $37.93B | $123.04B |
Dividend Yield | 1.59% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $88.56, up 1.57% today, with a bullish technical trend and strong recent earnings beats. The stock shows robust gross margins of 74.71% but faces profitability challenges with a negative net income margin. Analyst consensus is mixed with a $91.67 price target, while recent news highlights new product launches and institutional accumulation.
Outlook remains cautiously optimistic given earnings momentum and brand strength, but high valuation multiples and inconsistent cash flow pose risks. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity in the beauty sector.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
